Our offering
Our offerings are designed around one goal: Improving the success of your viral vector project.
DINAMIQS provides a fully integrated, tailored manufacturing model offering its clients unmatched flexibility to advance their programs efficiently: from lead vector optimization via preclinical scale work, up to cGMP production in just 7 – 9 months. Ensuring seamless continuity across the value chain, DINAMIQS accelerates timelines, reduces operational complexity, and safeguards product quality, allowing clients to move their programs from concept to commercialization with confidence.
Explore our offering
Adeno associated virus (AAV)
Seamless support from R&D to commercial: Deep scientific AAV expertise combined with state-of-the art manufacturing technology and a highly experienced development and cGMP team, enables end-to-end services to guide your gene therapy program to success.
Lentivirus (LV)
Seamless support from R&D to commercial: Deep scientific Lentivirus (LV) expertise combined with state-of-the art manufacturing technology and a highly experienced development and cGMP team, enables end-to-end services to guide cell therapy programs to success.
Analytical services
DINAMIQS offers a comprehensive suite of assays for the characterization of AAV and LV products, fully aligned with regulatory requirements. Large panel of assays to characterize critical quality attributes (CQAs) identity, purity, potency, strength and safety are performed in-house, ensuring speed, consistency, and quality.
Fill-finish
Fill-finish is a critical final step in the manufacturing of AAV and LV based cell and gene therapies, where product integrity and sterility must be maintained without compromise. Bringing fill-finish in-house enables tighter process control, seamless integration with drug substance manufacturing, and reduced reliance on external partners.
Distinctive services and technologies
Distinctive technologies built around your program: From AI-enabled vector optimization and proprietary capsids to flexible cell line strategies, our continuously evolving development platform, digital quality systems, and regulatory expertise help accelerate your path to clinical and commercial success.
Off the shelf vectors
Ready-to-use AAV vectors and reference materials: High-quality, well-characterized reporter gene vectors, empty capsids, and replication-competent AAV (rcAAV) standards provide immediate access to the tools needed to accelerate research, assay development, process optimization, and analytical qualification.
What sets us apart
Scientific excellence, built for viral vectors
DINAMIQS combines deep scientific expertise with purpose-built infrastructure to accelerate viral vector development and manufacturing. Our team of internationally recognized experts supports customers from process design to GMP production, while our state-of-the-art, fully digital facilities are designed specifically for viral vectors, ensuring efficiency, quality, and direct access to experienced decision-makers.
Flexible platforms, designed around your program
We believe our process should adapt to your product—not the other way around. Our flexible manufacturing platform supports a wide range of viral vectors and allows customers to retain control of their programs, with portable processes, client-owned intellectual property, and the freedom to select suppliers and downstream processing solutions that best fit their needs.
From development to commercial supply with confidence
DINAMIQS provides a seamless path from preclinical development to commercial manufacturing, all from a single site. Backed by extensive regulatory and CMC expertise, a highly experienced team, and the strength and support of the Siegfried Group, we deliver reliable results, regulatory readiness, and a secure foundation for long-term success.
Our facilities
DINAMIQS brand new facility in Switzerland (Schlieren/ Zurich) is a modular Biosafety Level 2 (BSL-2), purpose-built manufacturing site designed for AAV and LV manufacturing inspected by Swissmedic in early 2026.
The facility comprises two independent Class C production suites and a Class B seed suite. The manufacturing capacity ranges from 20L to 1000L for both, clinical and commercial supply with integrated fill and finish capabilities all under one roof. Operations are based on single-use, closed system, suspension cell only processes.